munosorbent assay, and the degree of protection was determined by challenge in ligated ileal loops. Immunization with the holotoxin provided a strong antitoxin response and protection against all 10 challenge strains. Immunization with toxin from the LT'/ST' strain provided equally strong protection against all 10 strains, but immunization with toxin from the LT+/ST-strain yielded only a weak antitoxin response, moderate protection against challenge with LT+/ST-strains, and no protection against LT'/ST' strains, increasing by fivefold the immunization dosage of the LT+/ST-toxin failed to enhance protection. These observations (i) establish the fact that immunization with the LT holotoxin provides uniformly strong protection against heterologous serotypes and (ii) indicate that, for reasons which remain to be determined, the immunogenicity of the polymyxin-release LT from an LT'/ST' strain differs from that of an LT+/ST-strain.
Acute diarrheal disease caused by transient contamination of the small bowel by noninvasive, enterotoxigenic strains of Escherichia coli (ETEC) is widespread, particularly among children in underdeveloped countries and visitors to such places (21) . The only practical measure for control of this disorder is the development of an immunization program capable of preventing either intestinal colonization by these strains or the secretory abnormality that their enterotoxins produce. Such a program would need to provide protection against all ETEC strains, including heterologous somatic serotypes which produce the heat-labile (LT) and heat-stable (ST) toxins, either singly or together.
Only one of the three E. coli antigens that have been shown to provide immunological protection against contamination by ETEC strains in experimental animals appears to afford consistent protection against heterologous somatic serotypes. (i) Immunization with the somatic antigen evokes protection by inhibiting bacterial growth, but only against the homologous serotype (13) . (ii) Inmunization with specific fimbrial antigens (colonization factors) provides protection against heterologous somatic serotypes by inhibiting adherence and colonization of the bacteria on the surface of the intestinal mucosa, but it extends only to strains having homologous fimbrial antigens (1, 17) , and human ETEC strains are recognized to have at least two, and probably more, antigenically dissimilar fimbrial antigens (4, 15) . (iii) Inmunization with the LT toxin arouses an antitoxin response which protects against ETEC strains which produce LT, either alone (LT'/ST-) or in combination with ST (LT'/ST') (10) (11) (12) . The LT toxin produced by different somatic serotypes is thought to be antigenically homogeneous (21) , but the evidence establishing that immunization with LT provides protection against all heterologous serotypes is confined to the demonstration of variable degrees of passive neutralization of crude LT toxin by antisera raised against either intact organisms or crude preparations of LT toxin (7, 9, 22) .
This study had two purposes. The first was to determine whether immunization with a pure preparation of the LT holotoxin (HT) provides a uniform degree of protection against direct challenge with viable ETEC strains of different somatic serotypes. To (LT-/ST+) and PB 258 (LT+/ST-), necessitating the use of the polymyxin-release form of LT toxin from these strains; this material was purified by the methods described by Evans and his co-workers (5) . The polymyxin-release LT toxin derived from strain H 10407 is referred to as LT/ST toxin; that from strain PB 258 is referred to as LT/-toxin. Toxin dosages are expressed in micrograms of protein as determined by the method of Lowry et al. (16) .
Polyacrylamide gel electrophoresis in sodium dodecyl sulfate (3) confirmed the homogeneity of the HT but showed the polymyxin-release toxins to consist of multiple protein bands. LT/ST toxin had (per microgram of protein) 1.6 jig, and LT/-toxin had 0.11 ,ug, of material that gave a positive reaction for 2-keto-3-deoxyoctonate (18) , indicating the presence of lipopolysaccharide (LPS); the HT had none. The HT was considerably more active in biological assay systems than the polymyxin-release LT toxins. for HT, 1,600 for LT/ST toxin, and 400 for LT/-toxin. LPS was prepared from strains H 10407 and PB 258 by the method of Westphal and Jahn (25), using multiple ultracentrifugations for purification.
Immunization procedures. Sprague-Dawley weanling rats were immunized by parenteral primary immunization followed by four weekly peroral booster immunizations. The parenteral immunization was given intraperitoneally, using Freund complete adjuvant (Difco Laboratories, Detroit, Mich.). The peroral immunizations were given via an intragastric tube 2 h after the peroral administration of cimetidine (Tagamet; Smith Kline & French Laboratories, Carolina, P.R.) as a dosage of 50 mg per kg of body weight, an amount shown to ablate gastric secretions in rats (2) . The primary immunization dosage was 100,g in all instances; unless otherwise specified, peroral booster dosages were 250 yg of LT/-and LT/ST toxins, 50 yg of HT in rats challenged with viable strains, and 250,g of HT in those challenged with toxin.
Challenge procedures. Rats were challenged 1 week after the final booster immunization by instilling into a single 10-cm ligated loop of distal ileum, for 18 h, either toxin or viable organisms, using previously described techniques (10) . Each datum point was determined by tests in two or more rats. Protection against toxin was determined by challenge with graded dosages of LT/ST toxin; this approach has been shown to yield equivalent results for protection after immunization with different LT toxin forms (12) . The protection index was determined by dividing that dosage in immunized rats which yielded the same secretion as the 50% effective dose in unimmunized rats by the 50% effective dose for unimmunized rats. For challenge with viable cultures, 0.1 ml of a culture broth containing 109 organisms per ml was used; this concentration has been found to be the minimum amount necessary to yield maximum secretion in ligated loops of unimmunized rats (10) . The values reported are the mean ± standard error of the mean for the degree of reduced secretion in immunized rats as compared with unimmunized rats challenged with viable organisms of the same strain.
Challenge strains. Strains of all 10 serotypes were positive in the Y1 adrenal cell assay for LT, and all five of the LT'/ST' strains were positive in the suckling mouse assay (6) for ST. (Eight strains were kindly provided by Bernard Rowe.) Antitoxin assays. Serum antibody titers were determined by ELISA (12), using HT as the antigen for sera from rats immunized with the LT toxins and the specific LPS preparations for sera from rats immunized with this material. The optimum concentration of each antigen was determined by checkerboard titration, HT against goat hyperimmune serum to HT and the LPS preparations against rabbit antiserum to E. coli serotype 078 or 015 (Difco). Values reported are for the increase in the reciprocal of the geometric mean titer in immunized rats compared with the value for control sera, derived from 20 unimmunized rats, assayed with that specific antigen.
RESULTS
Immunization with LT toxins. (i) Challenge with toxin. The protection index against challenge with toxin was 13.0 in rats immunized with HT, 10 .0 in those immunized with LT/ST toxin, and 2.6 in those immunized with LT/-toxin. Increasing the booster dosage of LT/-toxin, by either twofold to 500 jig or fivefold to 1,250,ug, failed to produce a significant increase in the protection index (Fig. 1) .
( (24) , and the addition of this material to cholera toxin or (23) . This has led to the suggestion that a combination of V. cholerae LPS and the cholera toxin B subunit may represent the optimal antigen for immunological protection against cholera (8) . Such does not appear to be the case for immunization against ETEC strains, however, since the E. coli LT toxin B subunit is considerably less antigenic on a molar basis than HT (12), and we found that immunization with purified preparations of E. coli LPS does not protect against challenge with heterologous serotypes. Although the LPS contaminant may have provided an adjuvant effect for the polymyxin-release LT toxins, the homogeneous HT, which contains no LPS, is the most immunogenic form of LT (12) , and the use of adjuvants for this material that are less toxic than LPS would seem preferable.
